Equilis Prequenza

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

sani virusa gripe: A / kopitarji-2 / Južna Afrika / 4/03, A / konjun-2 / Newmarket / 2/93

Available from:

Intervet International BV

ATC code:

QI05AA01

INN (International Name):

vaccine against equine influenza in horses

Therapeutic group:

Konji

Therapeutic area:

kopitarjev, virus influence

Therapeutic indications:

Aktivna imunizacija konjev od šestih mesecev starosti proti konjski influenci za zmanjšanje kliničnih znakov in izločanje virusa po okužbi.

Product summary:

Revision: 9

Authorization status:

Pooblaščeni

Authorization date:

2005-07-08

Patient Information leaflet

                                13
B.
NAVODILO ZA UPORABO
14
NAVODILO ZA UPORABO
Equilis Prequenza, suspenzija za injiciranje za konje
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
IMETNIKA DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVORNEGA ZA
SPROSTITEV SERIJE, ČE STA RAZLIČNA
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
Nizozemska
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Equilis Prequenza, suspenzija za injiciranje, za konje
3.
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGIH SESTAVIN
En odmerek (1 ml) vsebuje:
UČINKOVINE
Sevi virusa influence konj:
A/konjski-2/ Južna Afrika/4/03
50 AU
1
A/konjski-2/ Newmarket/2/93
50 AU
¹ antigenske ELISA enote
DODATEK
Iscom-Matrica, ki vsebuje:
Prečiščeni saponin
375
mikrogramov
Holesterol
125 mikrogramov
Fosfatidilholin
62,5 mikrogramov
Bistra opalescentna suspenzija.
4.
INDIKACIJA(E)
Aktivna imunizacija konj po šestem mesecu starosti proti influenci
konj za zmanjšanje kliničnih znakov
in izločanja virusa po okužbi.
Influenca
Razvoj imunosti:
2 tedna po osnovnem cepljenju
Trajanje imunosti:
5 mesecev po osnovnem cepljenju
12 mesecev po prvi revakcinaciji
5.
KONTRAINDIKACIJE
Jih ni.
6.
NEŽELENI UČINKI
15
Redko se pojavi neostro omejena trda ali mehka oteklina (premera
največ 5 cm) na mestu vboda, ki
mine v 2 dneh. V redkih primerih je možna bolečina na mestu dajanja,
ki lahko povzroči začasno
funkcijsko neugodje (togost). V zelo redkih primerih se lahko pojavi
lokalna reakcija, ki je večja od 5
cm in ki lahko traja dlje kot 2 dni. V zelo redkih primerih se lahko
pojavi vročina, včasih z letargijo in
neješčnostjo, ki traja 1 dan, izjemoma do 3 dni.
Pogostost neželenih učinkov je določena po naslednjem dogovoru:
- zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10
zdravljenih živali)
- pogosti (pri več kot 1, toda manj kot 10 živali od 100 zdravljenih
živali)
- občasni (pri več kot 1, toda manj kot 10 živali od 1.000
zdravljenih živali)
- redki (pri več kot 1, toda manj kot 10 živali od 10.000
zdravljenih živali)
- 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-12-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-12-2020
Public Assessment Report Public Assessment Report Bulgarian 23-05-2013
Patient Information leaflet Patient Information leaflet Spanish 16-12-2020
Public Assessment Report Public Assessment Report Spanish 23-05-2013
Patient Information leaflet Patient Information leaflet Czech 16-12-2020
Public Assessment Report Public Assessment Report Czech 23-05-2013
Patient Information leaflet Patient Information leaflet Danish 16-12-2020
Public Assessment Report Public Assessment Report Danish 23-05-2013
Patient Information leaflet Patient Information leaflet German 16-12-2020
Public Assessment Report Public Assessment Report German 23-05-2013
Patient Information leaflet Patient Information leaflet Estonian 16-12-2020
Public Assessment Report Public Assessment Report Estonian 23-05-2013
Patient Information leaflet Patient Information leaflet Greek 16-12-2020
Public Assessment Report Public Assessment Report Greek 23-05-2013
Patient Information leaflet Patient Information leaflet English 16-12-2020
Public Assessment Report Public Assessment Report English 23-05-2013
Patient Information leaflet Patient Information leaflet French 16-12-2020
Public Assessment Report Public Assessment Report French 23-05-2013
Patient Information leaflet Patient Information leaflet Italian 16-12-2020
Public Assessment Report Public Assessment Report Italian 23-05-2013
Patient Information leaflet Patient Information leaflet Latvian 16-12-2020
Public Assessment Report Public Assessment Report Latvian 23-05-2013
Patient Information leaflet Patient Information leaflet Lithuanian 16-12-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-12-2020
Public Assessment Report Public Assessment Report Lithuanian 23-05-2013
Patient Information leaflet Patient Information leaflet Hungarian 16-12-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 16-12-2020
Public Assessment Report Public Assessment Report Hungarian 23-05-2013
Patient Information leaflet Patient Information leaflet Maltese 16-12-2020
Public Assessment Report Public Assessment Report Maltese 23-05-2013
Patient Information leaflet Patient Information leaflet Dutch 16-12-2020
Public Assessment Report Public Assessment Report Dutch 23-05-2013
Patient Information leaflet Patient Information leaflet Polish 16-12-2020
Public Assessment Report Public Assessment Report Polish 23-05-2013
Patient Information leaflet Patient Information leaflet Portuguese 16-12-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 16-12-2020
Public Assessment Report Public Assessment Report Portuguese 23-05-2013
Patient Information leaflet Patient Information leaflet Romanian 16-12-2020
Public Assessment Report Public Assessment Report Romanian 23-05-2013
Patient Information leaflet Patient Information leaflet Slovak 16-12-2020
Public Assessment Report Public Assessment Report Slovak 23-05-2013
Patient Information leaflet Patient Information leaflet Finnish 16-12-2020
Public Assessment Report Public Assessment Report Finnish 23-05-2013
Patient Information leaflet Patient Information leaflet Swedish 16-12-2020
Public Assessment Report Public Assessment Report Swedish 23-05-2013
Patient Information leaflet Patient Information leaflet Norwegian 16-12-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 16-12-2020
Patient Information leaflet Patient Information leaflet Icelandic 16-12-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 16-12-2020